LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: logicbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/3/2022 | Outperform → Market Perform | William Blair | |
| 2/2/2022 | $16.00 → $6.00 | Hold | Chardan Capital |
| 12/23/2021 | $20.00 → $16.00 | Buy | Chardan Capital |
| 11/17/2021 | $24.00 → $8.00 | Overweight | Barclays |
| 11/16/2021 | $17.00 → $16.00 | Market Outperform | JMP Securities |
Fastest customizable press release news feed in the world
OAKLAND, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and six months ended June 30, 2025. Company Update On July 24, 2025, subsequent to the quarter-end, the Company's stockholders approved, and, on August 7, 2025, the Company completed, a reorganization under Section 251 of the Delaware General Corporation Law. Second-Quarter 2025 Financial Highlights Net loss was $5 million, compared to a net loss of $13 million in the second quarter of fiscal year 2024.As of June 30, 2025, the Company had $27 million in cash and cash equivalents, $192 million in ma
OAKLAND, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC), a Delaware corporation ("ContextLogic Holdings," the "Company," "we" or "our") today announced the completion of its plan of reorganization in connection with the Second Amended and Restated Agreement and Plan of Reorganization (the "Second A&R Reorganization Agreement") by and among the Company, ContextLogic Inc., a Delaware corporation ("ContextLogic"), and Easter Merger Sub, Inc., a Delaware corporation ("Merger Sub"), pursuant to which ContextLogic became a wholly owned subsidiary of ContextLogic Holdings. The reorganization was approved by ContextLogic stockholders at the Annual Meeting held o
OAKLAND, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (OTCQB:LOGC), ("ContextLogic" or the "Company") today announced it will report its second quarter 2025 financial results after the close of market on Thursday, August 7, 2025. ContextLogic's CEO Rishi Bajaj, CFO Michael Scarola, and VP of Investments Janak Goyani, will host a conference call and webcast for shareholders that afternoon at 5:00 PM ET / 2:00 PM PT. ContextLogic management will read from a prepared script and there will be no presentation or question-and-answer section in this quarter's call. The call will conclude at the end of our prepared remarks. Information about the Company's financial results, includi
Bajaj brings broad financial and strategic experience to Digimarc Board as the company builds the trust layer for the modern world. Digimarc Corporation (NASDAQ:DMRC), a pioneer in digital watermarking technologies, today announced the appointment of Rishi Bajaj, founder and CIO of private investment firm Altai Capital Management, L.P. ("Altai") and CEO of ContextLogic Inc., to its Board of Directors. Bajaj's qualifications to serve on the board include extensive investment management, operational, and board experience, particularly in the technology sector. Alongside Bajaj's appointment, Digimarc has entered into a cooperation agreement with Bajaj and Altai Capital Management, L.P.. Th
OAKLAND, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today reminds stockholders to vote "FOR" the proposed reorganization plan (the "Reorganization" or "Reorganization Proposal") at the upcoming Annual Meeting of Stockholders (the "Annual Meeting"). The Annual Meeting is scheduled to be held at 10:00 a.m. Pacific Time on July 24, 2025. Stockholders of record as of May 19, 2025 are entitled to vote. Every day that approval of the Reorganization is delayed puts the value of the Company's NOLs and your investment at risk. Regardless of the number of shares you own, your vote on the proposal to approve the Reorgan
Approximately 99% of Shares Voted have been "FOR" the Reorganization Proposal Additional Shares Needed to Vote "FOR" to Approve the Reorganization Urges ALL Stockholders to Protect the Value of their Investment by Voting "FOR" the Reorganization Proposal TODAY OAKLAND, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today announced its Annual Meeting of Stockholders (the "Annual Meeting") being held today will convene and then adjourn without conducting any business. The Annual Meeting will reconvene at 10:00 a.m. Pacific Time on July 24, 2025. The Annual Meeting was being held in connection with the Company's prop
OAKLAND, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (OTC:LOGC) ("ContextLogic," the "Company," "we" or "our") today announced the appointment of Michael Scarola as Chief Financial Officer, effective June 30, 2025. "We are thrilled to appoint Michael Scarola to the position of Chief Financial Officer. This appointment reflects our strategy to streamline our business as much as possible while we pursue value maximation through organic growth and accretive acquisitions." said Rishi Bajaj, Chief Executive Officer. Mr. Scarola currently serves as the Chief Financial Officer, Chief Operating Officer, and Chief Compliance Officer of Altai Capital, and has developed a wide a
OAKLAND, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today announced its intention to voluntarily delist from The Nasdaq Global Market at the close of markets on June 2, 2025 and to begin trading on the OTCQB® Venture Market of the OTC Markets on June 3, 2025. The Company is pleased to announce that the Company has been accepted for listing on the OTCQB® Venture Market of the OTC Markets (the "OTC Markets") and that the Company's Class A Common Stock, par value $0.0001 per share (the "Common Stock") will commence trading on the OTC Markets on Tuesday, June 3, 2025 under the ticker symbol "LOGC". Shareholders will
OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a
OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering
SCHEDULE 13G - ContextLogic Inc. (0001822250) (Subject)
15-12G - ContextLogic Inc. (0001822250) (Filer)
8-K/A - ContextLogic Inc. (0001822250) (Filer)
S-8 POS - ContextLogic Inc. (0001822250) (Filer)
S-8 POS - ContextLogic Inc. (0001822250) (Filer)
S-8 POS - ContextLogic Inc. (0001822250) (Filer)
S-8 POS - ContextLogic Inc. (0001822250) (Filer)
S-8 POS - ContextLogic Inc. (0001822250) (Filer)
S-8 POS - ContextLogic Inc. (0001822250) (Filer)
S-8 POS - ContextLogic Inc. (0001822250) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
William Blair downgraded LogicBio Therapeutics from Outperform to Market Perform
Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Hold and set a new price target of $6.00 from $16.00 previously
Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Buy and set a new price target of $16.00 from $20.00 previously
Barclays reiterated coverage of LogicBio Therapeutics with a rating of Overweight and set a new price target of $8.00 from $24.00 previously
JMP Securities reiterated coverage of LogicBio Therapeutics with a rating of Market Outperform and set a new price target of $16.00 from $17.00 previously
HC Wainwright & Co. initiated coverage of LogicBio Therapeutics with a rating of Buy and set a new price target of $15.00
JMP Securities initiated coverage of LogicBio Therapeutics with a rating of Outperform and set a new price target of $17.00
JMP Securities initiated coverage of LogicBio Therapeutics with a rating of Outperform and set a new price target of $17.00
JMP Securities initiated coverage of LogicBio Therapeutics with a rating of Outperform
JMP Securities initiated coverage of LogicBio Therapeutics with a rating of Mkt Outperform and set a new price target of $17.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ContextLogic Inc. (0001822250) (Issuer)
3 - ContextLogic Inc. (0001822250) (Issuer)
4 - ContextLogic Inc. (0001822250) (Issuer)
4 - ContextLogic Inc. (0001822250) (Issuer)
4 - ContextLogic Inc. (0001822250) (Issuer)
4 - ContextLogic Inc. (0001822250) (Issuer)
4 - ContextLogic Inc. (0001822250) (Issuer)
3 - ContextLogic Inc. (0001822250) (Issuer)
3 - ContextLogic Inc. (0001822250) (Issuer)
3 - ContextLogic Inc. (0001822250) (Issuer)
Live finance-specific insights
OAKLAND, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ContextLogic Holdings Inc. (OTCQB:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and six months ended June 30, 2025. Company Update On July 24, 2025, subsequent to the quarter-end, the Company's stockholders approved, and, on August 7, 2025, the Company completed, a reorganization under Section 251 of the Delaware General Corporation Law. Second-Quarter 2025 Financial Highlights Net loss was $5 million, compared to a net loss of $13 million in the second quarter of fiscal year 2024.As of June 30, 2025, the Company had $27 million in cash and cash equivalents, $192 million in ma
OAKLAND, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (OTCQB:LOGC), ("ContextLogic" or the "Company") today announced it will report its second quarter 2025 financial results after the close of market on Thursday, August 7, 2025. ContextLogic's CEO Rishi Bajaj, CFO Michael Scarola, and VP of Investments Janak Goyani, will host a conference call and webcast for shareholders that afternoon at 5:00 PM ET / 2:00 PM PT. ContextLogic management will read from a prepared script and there will be no presentation or question-and-answer section in this quarter's call. The call will conclude at the end of our prepared remarks. Information about the Company's financial results, includi
OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a
OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering
OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along
OAKLAND, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic," the "Company," "we" or "our") today announced it will report its fourth quarter and full year 2024 financial results after the close of market on Wednesday, March 12, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Mr. Bajaj and Mr. Goldthorpe will briefly discuss the company's fourth quarter results as well as provide additional commentary on the recently announced strategic investment and commitment made by BC Partners into Context
As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033. Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact
Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country. The rare diseases market was valued at
Visiongain has published a new report entitled Rare Diseases 2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, Others), Market Segment by Type (Non-biologics, Biologics), Market Segment by End-users (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies), Market Segment by Age (Adult, Paediatric), plus COVID-19 Impact Analysis and Recovery Pattern Analysis ("V"-shaped, "W"-shaped, "U"-shaped, "L"-shaped), Profiles of Leading Companies, Region and Country. The rare diseases market was valued a
LEXINGTON, Mass., Feb. 2, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development program. The U.S. Food and Drug Administration (FDA) has notified the company that its Phase 1/2 SUNRISE clinical trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA) has been placed on clinical hold. The company will host a conference call and webcast this morning to discuss this update. To date, four patients have been dosed in the SUNRISE trial with LB-001, LogicBio's investigational, single-administration, adeno-associated virus (AAV) genome editing therapy. In accordance with th
Live Leadership Updates
Bajaj brings broad financial and strategic experience to Digimarc Board as the company builds the trust layer for the modern world. Digimarc Corporation (NASDAQ:DMRC), a pioneer in digital watermarking technologies, today announced the appointment of Rishi Bajaj, founder and CIO of private investment firm Altai Capital Management, L.P. ("Altai") and CEO of ContextLogic Inc., to its Board of Directors. Bajaj's qualifications to serve on the board include extensive investment management, operational, and board experience, particularly in the technology sector. Alongside Bajaj's appointment, Digimarc has entered into a cooperation agreement with Bajaj and Altai Capital Management, L.P.. Th
OAKLAND, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (OTC:LOGC) ("ContextLogic," the "Company," "we" or "our") today announced the appointment of Michael Scarola as Chief Financial Officer, effective June 30, 2025. "We are thrilled to appoint Michael Scarola to the position of Chief Financial Officer. This appointment reflects our strategy to streamline our business as much as possible while we pursue value maximation through organic growth and accretive acquisitions." said Rishi Bajaj, Chief Executive Officer. Mr. Scarola currently serves as the Chief Financial Officer, Chief Operating Officer, and Chief Compliance Officer of Altai Capital, and has developed a wide a
Strategic investment and capital commitment positions the Company to execute on its stated acquisition-led value maximization strategy; ContextLogic to have up to $300 million of investible cash Ted Goldthorpe, Head of BC Partners Credit, expected to be named Chairman of the Board OAKLAND, Calif. and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") and BC Partners, an alternative investment manager with c.€40 billion in assets under management, today announced that a fund advised by BC Partners Advisors L.P. will purchase up to $150 million of convertible preferred units (the "Preferred Units") of ContextLogic Holdings, L
LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates. "At LogicBio, we are continuing to advance our mission to safely deliver novel genetic medicines to people impacted by devastating, early onset diseases," said Frederic Chereau, president and chief executive officer of LogicBio. "We are pleased to report that the serious adverse event experienced by the fourth patient enrolled in our Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia has resolved." Recent Business Update
LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the promotion of Daniel Gruskin, MD, as chief medical officer. Dr. Gruskin most recently served as senior vice president and head of clinical development. The Company also announced the appointment of Stephen Boyer, PhD, as vice president of regulatory and quality affairs, and Peter Pechan, PhD, as vice president of gene therapy, who will support progress in the Phase I/II SUNRISE clinical trial of LB-001, the Company's investi
LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the appointment of Andrea Paul as general counsel and corporate secretary and Janice Olson as senior vice president of strategy and portfolio management. Ms. Paul and Ms. Olson are both seasoned industry experts with extensive experience in the pharmaceutical and biotechnology industries including in the gene therapy and rare disease sectors. "It is an exciting time at LogicBio with ongoing efforts to expand the reach of our G
This live feed shows all institutional transactions in real time.
SC 13G/A - ContextLogic Inc. (0001822250) (Subject)
SC 13G/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)
SC 13D/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)
SC 13G/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)
SC 13G - LogicBio Therapeutics, Inc. (0001664106) (Subject)
SC 13D/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)
SC 13D/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)
SC 13G/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)
SC 13D/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)
SC 13G/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)